ArticleCancer reports (Hoboken, N.J.)2021

ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study.

Marit A C Vermunt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.